Chikungunya virus (CHIKV) causes an acute febrile disease ... Currently, there is no effective antiviral treatment for CHIKV infection or disease. However, there are several vaccine candidates ...

This means they can be infected and if bitten by another mosquito can introduce the virus into the local mosquito population. There is no antiviral medicine to treat chikungunya viral infection.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

Currently no treatment for the infection is available although a vaccine is being developed in US. As per the new Lancet research, people infected with chikungunya virus remain at increased risk ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second phase 3 trial, in hot ...